Medite Cancer Diagnostics Inc Overview
- Founded
-
1998
- Status
-
Acquired/Merged
- Employees
-
80
- Latest Deal Type
-
M&A
- Financing Rounds
-
5
- Investments
-
1
Medite Cancer Diagnostics Inc General Information
Description
Medite Cancer Diagnostics Inc is a US-based company which specializes in the marketing and selling of MEDITE core products (instruments and consumables), manufacturing, development of new solutions in histology and cytology and marketing of molecular biomarkers. The company manufactures medical devices and consumables are for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. Medite operates through the single segment for cancer diagnostics instruments and consumables for histology and cytology laboratories. It offers a range of histology laboratory devices for processing tissue, from receiving the tissue in the laboratory to the final diagnosis.
Contact Information
Website
www.cytocoreinc.com
Formerly Known As
Molecular Diagnostics, Cytocore
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Diagnostic Equipment
Other Industries
Other Devices and Supplies
Acquirer
Primary Office
- 414 North Orleans Street
- Suite 510
- Chicago, IL 60654
- United States
Medite Cancer Diagnostics Inc Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Medite Cancer Diagnostics Inc Patents
Medite Cancer Diagnostics Inc Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-9880156-B2 | Biological specimen evaluation methods using cytology and immunology | Expired - Fee Related | 11-Apr-2013 | 00000000000 | |
| US-20160033482-A1 | Biological specimen evaluation methods using cytology and immunology | Granted | 11-Apr-2013 | 00000000000 | |
| EP-2984487-A4 | Biological specimen evaluation methods using cytology and immunology | Granted | 11-Apr-2013 | 00000000000 | 0 |
| ES-2735994-T3 | Method to estimate the risk of dysplasia evolving into cancer in a subject | Active | 11-Apr-2013 | 00000000000 | |
| EP-2984487-B1 | Method for estimating the risk of dysplasia progressing to cancer in a subject | Not-In-Force | 11-Apr-2013 | G01N33/5091 |
Medite Cancer Diagnostics Inc Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000 000000 | Self | Board Member | 000 0000 |
| 0000000 00000 00 | Self | Chairman & Board Member | 000 0000 |
Medite Cancer Diagnostics Inc Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Medite Cancer Diagnostics Inc Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Medite Cancer Diagnostics Inc Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 04-Apr-2014 | 0000000 00 | Diagnostic Equipment |